Cardlytics, Inc. (NASDAQ:CDLX) Receives $6.92 Average PT from Brokerages

Cardlytics, Inc. (NASDAQ:CDLX) has received an average rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $6.92.

CDLX has been the topic of several research analyst reports. Evercore ISI started coverage on shares of Cardlytics in a report on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target on the stock. Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th.

Cardlytics Stock Performance

Shares of CDLX opened at $3.35 on Friday. Cardlytics has a 52-week low of $2.89 and a 52-week high of $20.52. The stock’s 50-day simple moving average is $3.87 and its 200 day simple moving average is $4.76. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a market capitalization of $170.25 million, a price-to-earnings ratio of -0.55 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. Cardlytics’s revenue was down 15.1% compared to the same quarter last year. During the same period last year, the business earned ($0.26) earnings per share. Research analysts forecast that Cardlytics will post -1.52 EPS for the current fiscal year.

Insider Buying and Selling at Cardlytics

In other news, CFO Alexis Desieno sold 8,854 shares of the company’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total value of $32,494.18. Following the completion of the sale, the chief financial officer now owns 121,976 shares of the company’s stock, valued at approximately $447,651.92. This represents a 6.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares in the company, valued at approximately $687,298.15. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,007 shares of company stock worth $251,297 over the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Institutional Trading of Cardlytics

Several institutional investors have recently added to or reduced their stakes in CDLX. RBF Capital LLC increased its stake in shares of Cardlytics by 311.9% in the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after buying an additional 369,620 shares during the period. GSA Capital Partners LLP grew its holdings in Cardlytics by 1,273.2% in the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after acquiring an additional 354,474 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock valued at $2,882,000 after acquiring an additional 307,800 shares during the period. Jacobs Levy Equity Management Inc. increased its position in shares of Cardlytics by 56.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company’s stock valued at $1,016,000 after acquiring an additional 113,966 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Cardlytics by 7.5% during the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after acquiring an additional 73,484 shares during the last quarter. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.